Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 2/20 | 0.70 |
| ▸ | MAOB | P27338 | 6/20 | 0.62 |
| ▸ | MAOA | P21397 | 3/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | NPC1 | O15118 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.62 |
| ▸ | RAB9A | P51151 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.62 |
| ▸ | ACHE | P22303 | 3/20 | 0.57 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17185522 | 0.94 | ABCB1 (0.72) | ABCB1MAOBMAOAKDM4EMEN1 | |
| SCHEMBL19129506 | 0.92 | MAOB (0.60) | ABCB1MAOBMAOAACHESIGMAR1 | |
| SCHEMBL17193740 | 0.87 | ABCB1 (0.73) | ABCB1MAOBMAOAKDM4EMEN1 | |
| SCHEMBL17185536 | 0.87 | ABCB1 (0.73) | ABCB1MAOBMAOAKDM4EMEN1 | |
| SCHEMBL17193741 | 0.86 | MAOB (0.81) | ABCB1MAOBMAOAKDM4EMEN1 | |
| SCHEMBL17185543 | 0.86 | ABCB1 (0.69) | ABCB1MAOBMAOAKDM4EMEN1 | |
| SCHEMBL19129741 | 0.86 | MAOB (0.61) | ABCB1MAOBMAOAACHESIGMAR1 | |
| SCHEMBL17185524 | 0.85 | ABCB1 (0.75) | ABCB1MAOBMAOAKDM4EMEN1 | |
| SCHEMBL17185542 | 0.85 | ABCB1 (0.75) | ABCB1MAOBMAOAKDM4EMEN1 | |
| SCHEMBL17185533 | 0.85 | ABCB1 (0.75) | ABCB1MAOBMAOAKDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170204078-A1 | APIGENIN ANALOGS, COMPOSITIONS, AND METHODS RELATED THERETO | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2017-07-20 | — | — | US | claimed |
| WO-2015161309-A1 | APIGENIN ANALOGS, COMPOSITIONS, AND METHODS RELATED THERETO | ZHOU JIA (US) | 2015-10-22 | — | — | WO | claimed |
| US-9868715-B2 | Apigenin analogs, compositions, and methods related thereto | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEMS (US) | 2018-01-16 | — | — | US | disclosed |
| US-9868715-B2 | Apigenin analogs, compositions, and methods related thereto | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEMS (US) | 2018-01-16 | — | — | US | disclosed |
| US-20170204078-A1 | APIGENIN ANALOGS, COMPOSITIONS, AND METHODS RELATED THERETO | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2017-07-20 | — | — | US | disclosed |
| US-20170204078-A1 | APIGENIN ANALOGS, COMPOSITIONS, AND METHODS RELATED THERETO | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2017-07-20 | — | — | US | disclosed |
| WO-2015161309-A1 | APIGENIN ANALOGS, COMPOSITIONS, AND METHODS RELATED THERETO | ZHOU JIA (US) | 2015-10-22 | — | — | WO | disclosed |
| WO-2015161309-A1 | APIGENIN ANALOGS, COMPOSITIONS, AND METHODS RELATED THERETO | ZHOU JIA (US) | 2015-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170204078-A1 | APIGENIN ANALOGS, COMPOSITIONS, AND METHODS RELATED THERETO | CBS, CTH, PTGIS | ABCB1 831/4885MAOB 1245/4885MAOA 1595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.